Palmer JD, et al. - Researchers examined the value of rapid early tumor progression before radiation and chemotherapy for the prognosis of glioblastoma patients. They performed a retrospective review of 87 patients and identified rapid early progression (REP: new enhancing tumor or >25% increase in enhancement) development in a total of 52% of patients. Findings thus revealed a common encounter to REP in these cases. It was noted to be independently predictive for worse overall survival. They observed improved prognostic assessment when REP was integrated with MGMT promotor methylation. Tumor progression was commonly observed at the site of REP. As per findings, there is a particular subset of glioblastoma patients who are resistant to the current standard of care therapy.